Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.91 USD
Change Today -0.13 / -0.38%
Volume 303.2K
PRTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (PRTA) Snapshot

Open
$33.59
Previous Close
$34.04
Day High
$34.49
Day Low
$33.01
52 Week High
03/20/15 - $45.00
52 Week Low
08/1/14 - $16.71
Market Cap
1.1B
Average Volume 10 Days
236.5K
EPS TTM
$-1.45
Shares Outstanding
31.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (PRTA)

Related News

No related news articles were found.

prothena corp plc (PRTA) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (PRTA) Details

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion in Ireland. The company’s product pipeline includes NEOD001, a product candidate that is in Phase III clinical trials to treat patients with AL amyloidosis, as well as is in Phase I/II clinical trials for AL amyloidosis and persistent organ dysfunction. It is also developing PRX002 that is in Phase I clinical trials for the treatment of Parkinson’s disease and other synucleinopathies; and PRX003, a monoclonal antibody for psoriasis and other inflammatory diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

46 Employees
Last Reported Date: 03/13/15
Founded in 2012

prothena corp plc (PRTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $491.7K
Chief Financial Officer
Total Annual Compensation: $338.3K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $398.3K
Chief Medical Officer
Total Annual Compensation: $348.5K
Chief Legal Officer
Total Annual Compensation: $217.9K
Compensation as of Fiscal Year 2014.

prothena corp plc (PRTA) Key Developments

Prothena Corporation plc to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO Annual Meeting

Prothena Corporation plc announced that updated clinical data, from the multiple ascending dose portion of its ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction, will be highlighted in an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 29 – June 2, 2015 in Chicago, IL. In addition, there will be a poster presentation on the study design of Prothena's VITAL Amyloidosis Study, a randomized, double-blind, placebo-controlled, global Phase 3 study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.

Prothena Corporation plc Presents at UBS Global Healthcare Conference, May-18-2015 10:30 AM

Prothena Corporation plc Presents at UBS Global Healthcare Conference, May-18-2015 10:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Tran B. Nguyen, Chief Financial Officer.

Prothena Corporation plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Prothena Corporation plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $15.2 million as compared to net income of $17.9 million for the first quarter of 2014. Net loss per diluted share was $0.55 for the quarter as compared to net income per share of $0.78 on a fully diluted basis for the first quarter of 2014. The company reported total revenue of $0.6 million for the quarter as compared to total revenue of $32.2 million for the first quarter of 2014. The decrease was primarily due to $32.1 million in collaboration revenue recognized in relation to the PRX002 collaboration with Roche in the first quarter of 2014 compared to $0.6 million in collaboration revenue recognized in the first quarter of 2015. Loss from operations was $15.0 million compared with income from operations of $18.0 million a year ago. Loss before income taxes was $14.94 million compared with income of $18.0 million a year ago. Net cash used in operating activities was $14.7 million in the quarter. The company expects the full year 2015 net cash burn from operating and investing activities to be $66 million to $72 million, ending the year with approximately $356 million in cash (mid-point). The estimated full year 2015 net cash burn from operating and investing activities is primarily driven by an estimated net loss of $77 million to $83 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTA:US $33.91 USD -0.13

PRTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTA.
View Industry Companies
 

Industry Analysis

PRTA

Industry Average

Valuation PRTA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.